Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
A phase 2 trial of APG2575 in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.
Overview
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL is a phase 2 interventional study registered as NCT05147467 by Ascentage Pharma Group Inc., with 75 participants planned, started 2021-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: APG2575.
Similar pages
not linked directly; found by shared links- TrialStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialA Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Shares Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Chronic lymphocytic leukaemia and the tag pipeline.